Toll-like receptor–Mitogen-activated protein kinase signaling pathway (TLR–MAPK signaling)

The Toll-like receptor–Mitogen-activated protein kinase (TLR–MAPK) pro-inflammatory signaling pathway is a central axis of the innate immune system that translates the detection of pathogens or cellular damage into a robust inflammatory response (NIH, 2021). Toll-like receptors (TLRs) serve as pattern recognition receptors that, upon binding to ligands such as lipopolysaccharides or viral RNA, undergo dimerization and recruit adaptor proteins like MyD88 or TRIF (Frontiers in Immunology, 2020). This recruitment triggers a downstream kinase cascade involving IRAK and TAK1, which ultimately activates the MAPK family members, including p38, JNK, and ERK (R&D Systems, 2024). These kinases then modulate the activity of transcription factors such as NF-κB and AP-1, leading to the transcription of genes encoding pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6 (Assay Genie, 2024). While essential for host defense, aberrant or chronic activation of this pathway is a hallmark of various diseases, including sepsis, rheumatoid arthritis, and certain cancers (Uni.lu, 2024). Consequently, therapeutic interventions often target specific nodes within this pathway, such as TLR4 antagonists or p38 MAPK inhibitors, to mitigate excessive inflammation and its associated tissue damage (ResearchGate, 2024).

Other names

TLR-MAPK axisTLR-mediated MAPK activationToll-like receptor signaling pathwayTLR-MAPK pro-inflammatory signaling

Drugs targeting this pathway act by antagonizing Toll-like receptors (e.g., TLR4), inhibiting downstream kinases such as IRAK4 or TAK1, or directly inhibiting the catalytic activity of MAPKs like p38 and JNK to prevent the production of pro-inflammatory cytokines (NIH, 2021; Frontiers in Immunology, 2020).